 Reported 0.29 EPS from continuing operations and achieved 0.51 of adjusted EPS Recently acquired two high-growth, high-gross margin medical technology businesses Announced 2021 outlook with expectations for significant revenue, profit and cash flow growth Scheduled Investor Day for Thursday, March 11, 2021 